APVO Stock Performance, Insider Transaction and News

APVO - Aptevo Therapeutics Inc.

Market Cap	4.56M	P/E	0.20	EPS this Y	72.40%	Ern Qtrly Grth	-
Income	-25.25M	Forward P/E	-0.13	EPS next Y	66.20%	50D Avg Chg	-57.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	-71.00%
Dividend	N/A	Price/Book	0.19	EPS next 5Y	-	52W High Chg	-92.00%
Recommedations	2.00	Quick Ratio	1.49	Shares Outstanding	13.44M	52W Low Chg	4.00%
Insider Own	0.04%	ROA	-74.01%	Shares Float	8.89M	Beta	5.17
Inst Own	14.61%	ROE	-243.73%	Shares Shorted/Prior	13.02K/310.70K	Price	0.60
Gross Margin	-	Profit Margin	-	Avg. Volume	226,085	Target Price	9.25
Oper. Margin	-	Earnings Date	Nov 12	Volume	2,973,949	Change	-38.30%

Healthcare | Biotechnology | United States

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Aptevo Therapeutics Inc. News

11/20/24	First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
11/11/24	First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
11/07/24	Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
10/29/24	Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
09/18/24	Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
09/16/24	Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
09/16/24	Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
09/13/24	Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
08/13/24	Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
08/08/24	Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
07/01/24	Aptevo Therapeutics Announces Closing of $2.75 Million Offering
06/28/24	Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
06/03/24	Aptevo Participating in the BIO International Convention
05/14/24	Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
05/08/24	Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
04/15/24	Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
04/11/24	Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
04/10/24	Aptevo Therapeutics Provides Pipeline Update
03/18/24	Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
03/07/24	Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

APVO Chatroom

2LTL2L8 Posted - 29 minutes ago

$APVO Food for Thought... Sometimes, instead of using the crazy ass wicks for your trend, it's higher percentage to trend the intra-day VWAP peaks... It plays out more often then you'd think

slickinvest Posted - 6 hours ago

$APVO looks like she wants to burst !

CW630 Posted - 6 hours ago

$APVO nice recovery. watching.

isaacwilliams33 Posted - 17 hours ago

$STI it did the dip now it will rip and $APVO still Bullish.

BIGballs25 Posted - 18 hours ago

$APVO The fact that nobody is talking about this stock makes me think it will moon

BIGballs25 Posted - 18 hours ago

$APVO is this going to pump soon??

First_Class_Seaman Posted - 18 hours ago

$APVO about to make a move here soon $ABVE THIS IS BUYING MONEY AT DISCOUNT

topdownagain Posted - 22 hours ago

$APVO https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/first-patient-dosed-aptevos-ongoing-rainier-trial-achieves-90

2sexyBiatch Posted - 1 day ago

$MVST $APVO $CERO power hour runners

2sexyBiatch Posted - 1 day ago

$CERO $APVO LETS GO

Jd0909 Posted - 1 day ago

$APVO after lunch bounce!

slickinvest Posted - 1 day ago

$APVO week hands out let’s rock n roll!!

Mountain_Eagle Posted - 1 day ago

@2LTL2L8 whats happening with $APVO ?

2LTL2L8 Posted - 1 day ago

$APVO I see you

CW630 Posted - 1 day ago

$APVO .32 was the sell. Of course it didn't hold. You should've sold.

4Reel Posted - 1 day ago

$APVO and red, complete pump and dump

2sexyBiatch Posted - 1 day ago

$APVO this will pop up on radars today

Incinerazer86 Posted - 1 day ago

$APVO Grrrrr I'm soooo mad!!!

randompics Posted - 1 day ago

$APVO and back come the short scumbags. Took half hour to run this up .06 and took them 30 seconds to run it back down.

wellyesandno Posted - 1 day ago

$APVO .76 and you will never see me in here again

Incinerazer86 Posted - 1 day ago

$APVO Drats I bought this at $0.31 instead of XCUR. Now I'm down 😞😞😞

slickinvest Posted - 1 day ago

$APVO

randompics Posted - 1 day ago

$APVO People are really missing this one I believe. I don't see anything not to like. They need money, so someone is going to buy into this company sooner than later.

2sexyBiatch Posted - 1 day ago

$APVO is that a cup and handle forming on the 3 month?

CW630 Posted - 1 day ago

$APVO if this can get back over .32.. watching for now.

Biksi Posted - 1 day ago

$APVO I’m not an investor (visiting these boards to “oversee" my husband’s investments 😇) so I didn’t notice the below sentence in the PR (my husband did). It is saying that their investigators are keeping the biotechs they’re working with informed about the progress of this molecule. In other words, there’s an interest in this molecule in the industry. "These early findings have fueled excitement around RAINIER among the group of investigators at premier cancer treatment institutions who have been working with the drug and members of the biotechnology industry who have been following its progress."

Franklin_Atkinson_ Posted - 1 day ago

$APVO $EAST LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

max315 Posted - 1 day ago

$APVO leukemia news this morning watching for pmh break

randompics Posted - 1 day ago

$APVO most other stocks would be up 300% or more on this important news. This one gets shorted

randompics Posted - 1 day ago

$APVO amazing that the better the news that comes from this company, that harder the shorts dig in.

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
-	- -	Nov 06	Buy	17.82	1,436,675	25,601,548	1,760,000	11/06/20